Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation

Bibliography

• DAVIES M: The composition of coronary artery plaques. N Engl. I Med. (1997) 336:1312–1313.
   PubMed Web of Science ®Google Scholar
• LUSIS AJ: Atherosclerosis. Nature (2000) 407:233–241.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation (2001) 104:365–372.
   PubMed Web of Science ®Google Scholar
• •A thorough review of pathogenic mechanisms in ACS.
   Google Scholar
• FALK E, SHAH P, FUSTER V: Coronary plaque disruption. Circulation (1995) 92:657–671.
   PubMed Web of Science ®Google Scholar
• FARB A, BURKE AP, TANG AL et al: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation (1996) 93:1354–1363.
   Google Scholar
• HACKETT D, DAVIES G, MASERI A: Pre-existing coronary stenosis in patients with first infarction are not necessarily severe. Eur. Heart (1988) 9:1317–1323.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, SACCO DE, ALBERS JJ: Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation (1993) 87:1781–1791.
   Google Scholar
• BLANKENHORN DH, HODIS HN: Arterial imaging and atherosclerosis reversal. Arterioscler. Thromb. (1994) 14:177–192.
   PubMed Web of Science ®Google Scholar
• CHEN L, CHESTER MR, CROOK R, KASKI JC: Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris. J. Am. Coll. Cardiol (1996) 28:597–603.
   PubMedGoogle Scholar
• GOLDSTEIN JA, DEMETRIOU D, GRINES CL, PICA M, SHOUKFEH M, O'NEILL WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl. I. Med. (2000) 343:915–922.
   PubMed Web of Science ®Google Scholar
• GUAZZI MD, BUSSOTTI M, GRANCINI L et al: Evidence of multifocal activity of coronary disease in patients with acute myocardial infarction. Circulation (1997) 96:1145–1151.
   PubMedGoogle Scholar
• MAZZONE A, DE SERVI S, RICEVUTI G et al.: Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation (1993) 88:358–363.
   PubMedGoogle Scholar
• SERNERI GG, ABBATE R, GORI AM et al.: Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation (1992) 86:790–797.
   PubMed Web of Science ®Google Scholar
• HANSSON GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. (2005) 352:1685–1695.
   PubMed Web of Science ®Google Scholar
• ••An up-to-date review on inflammatoryprocesses in atherosclerosis.
   Google Scholar
• VAN DER WAL AC, BECKER AE, VAN DER LOOS CM, DAS PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation (1994) 89:36–44.
   PubMed Web of Science ®Google Scholar
• LIBBY P, GENG YJ, AIKAWA M et al.: Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol (1996) 7:330–335.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, HOLM J, JONASSON L: Detection of T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol (1989) 135:169–175.
   PubMed Web of Science ®Google Scholar
• BUFFON A, BIASUCCI LM, LIUZZO G, D'ONOFRIO G, CREA F, MASERI A: Widespread coronary inflammation in unstable angina. N Engl. Med. (2002) 347:5–12.
   PubMed Web of Science ®Google Scholar
• ••An early paper challenging the concept of asingle vulnerable plaque in unstable coronary syndromes.
   Google Scholar
• RIDKER PM, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl. I. Med. (2000) 342:836–843.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl. I. Med. (1997) 336:973–979.
   PubMed Web of Science ®Google Scholar
• •One of the first studies showing that plasma concentration of CRP predicts the risk of future myocardial infarction and stroke.
   Google Scholar
• RUGGERI ZM: Platelets in atherothrombosis. Nat. Med. (2002) 8:1227–1234.
   PubMed Web of Science ®Google Scholar
• •A detailed review on the participation of platelets in atherogenesis.
   Google Scholar
• DAM/86 JK, WiEHRE T, YNDESTAD A et al.: Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation (2003) 107:2670–2676.
   Google Scholar
• WAGNER DD, BURGER PC: Platelets ininflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. (2003) 23:2131–2137.
   PubMed Web of Science ®Google Scholar
• WEBER C: Platelets and chemokines in atherosclerosis: partners in crime. Circ. Res. (2005) 96:612–616.
   PubMed Web of Science ®Google Scholar
• NEUMANN FJ, MARX N, GAWAZ M et al: Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation (1997) 95:2387–2394.
   PubMed Web of Science ®Google Scholar
• WEYRICH AS, ELSTAD MR, MCEVER RP et al.: Activated platelets signal chemokine synthesis by human monocytes. Clin. Invest. (1996) 97:1525–1534.
   Google Scholar
• ••One of the first studies showing the abilityof platelets to promote an inflammatory response in monocytes.
   Google Scholar
• WiEHRE T, DAM/86 JK, YNDESTAD A et al.: Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells - potential role of prostaglandin E2. Thromb. Haemost. (2004) 92:1358–1367.
   Google Scholar
• CLEMETSON KJ, CLEMETSON JM, PROUDFOOT AE, POWER CA, BAGGIOLINI M, WELLS TN: Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood (2000) 96:4046–4054.
   PubMed Web of Science ®Google Scholar
• ••An interesting paper describing functionalexpression of several chemokine receptors on platelets.
   Google Scholar
• AMENTO EP, EHSANI N, PALMER H, LIBBY P: Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. (1991) 11:1223–1230.
   PubMed Web of Science ®Google Scholar
• GUPTA S, PABLO AM, JIANG X, WANG N, TALL AR, SCHINDLER C: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. (1997) 99:2752–2761.
   PubMed Web of Science ®Google Scholar
• •An interesting study demonstrating the pathogenic role of TH1 cytokines in atherogenesis.
   Google Scholar
• GALIS ZS, KHATRI JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. (2002) 90:251–262.
   PubMed Web of Science ®Google Scholar
• ••A detailed review on the role of MNIPs invascular remodelling.
   Google Scholar
• GALIS ZS, SUKHOVA GK, KRANZHOFER R, CLARK S, LIBBY P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA (1995) 92:402–406.
   PubMed Web of Science ®Google Scholar
• GALIS ZS, MUSZYNSKI M, SUKHOVA GK, SIMON-MORRISSEY E, LIBBY P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. NY Acad. Li. (1995) 748:501–507.
   PubMed Web of Science ®Google Scholar
• BROWN DL, HIBBS MS, KEARNEY M, LOUSHIN C, ISNER JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation (1995) 91:2125–2131.
   Google Scholar
• SCHONBECK U, MACH F, LIBBY P: Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase- 1-independent pathway of IL-1 beta processing. J. Immunol (1998) 161:3340–3346.
   PubMed Web of Science ®Google Scholar
• WALSH K, SMITH RC, KIM HS: Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ. Res. (2000) 87:184–188.
   PubMed Web of Science ®Google Scholar
• MARTINET W, KOCKX MM: Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation. Curh Opin. Lipidol (2001) 12:535–541.
   PubMed Web of Science ®Google Scholar
• VALGIMIGLI M, AGNOLETTI L, CURELLO S et al.: Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. Circulation (2003) 107:264–270.
   PubMed Web of Science ®Google Scholar
• GENG YJ, WU Q, MUSZYNSKI M, HANSSON GK, LIBBY P: Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. (1996) 16:19–27.
   PubMed Web of Science ®Google Scholar
• GENG YJ, LIBBY P: Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am. J. Pathol (1995) 147:251–266.
   Google Scholar
• FLYNN PD, BYRNE CD, BAGLIN TP, WEISSBERG PL, BENNETT MR: Thrombin generation by apoptotic vascular smooth muscle cells. Blood (1997) 89:4378–4384.
   PubMed Web of Science ®Google Scholar
• •An important study suggesting that apoptotic cells within atherosclerotic plaques may allow local thrombin activation.
   Google Scholar
• DAEMEN MA, VAN 'T VEER C, DENECKER G et al: Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J. Clin. Invest. (1999) 104:541–549.
   PubMed Web of Science ®Google Scholar
• KOLODGIE FD, NARULA J, BURKE APet al: Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. I Pathol (2000) 157:1259–1268.
   PubMed Web of Science ®Google Scholar
• PINDERSKI LJ, FISCHBEIN MP, SUBBANAGOUNDER G et al.: Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res. (2002) 90:1064–1071.
   PubMed Web of Science ®Google Scholar
• LIBBY P, AIKAWA M: Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat. Med. (2002) 8:1257–1262.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review describing variousclinical plaque-stabilising approaches.
   Google Scholar
• ALBERT MA, DANIELSON E, RIFAI N, RIDKER PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. "AMA (2001) 286:64–70.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl. I Med. (2005) 352:29–38.
   PubMed Web of Science ®Google Scholar
• ••An important clinical study showing thatthe reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.
   Google Scholar
• RIDKER PM, CANNON CP, MORROW D et al: C-reactive protein levels and outcomes after statin therapy. N Engl. J. Med. (2005) 352:20–28.
   PubMed Web of Science ®Google Scholar
• PEARSON TA: Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. Am. J. Cardiol. (1998) 82:28S–30S.
   Google Scholar
• YEUNG AC, TSAO P: Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation (2002) 105:2937–2938.
   PubMed Web of Science ®Google Scholar
• DAVIGNON J: Beneficial cardiovascularpleiotropic effects of statins. Circulation (2004) 109:11139–11143.
   Google Scholar
• WiEHRE T, DAM/86 JK, GULLESTAD L et al.: Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J. Am. Coll Cardiol (2003) 41:1460–1467.
   Google Scholar
• WiEHRE T, YNDESTAD A, SMITH C et al.: Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation (2004) 109: 1966-1972.
   Google Scholar
• AIKAWA M, RABKIN E, OKADA Y et al: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 97:2433–2444.
   PubMed Web of Science ®Google Scholar
• ••An important study describing that lipidlowering by diet may stabilise vulnerable plaques.
   Google Scholar
• SPARROW CP, BURTON CA, HERNANDEZ M et al.: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. (2001) 21:115–121.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6:1399–1402.
   PubMed Web of Science ®Google Scholar
• NI W, EGASHIRA K, KATAOKA C et al.: Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. (2001) 89:415–421.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687–692.
   PubMed Web of Science ®Google Scholar
• ••An interesting paper describing statineffects unrelated to the inhibition of HMG-CoA reductase.
   Google Scholar
• RIDKER PM, RIFAI N, CLEARFIELD Met al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl. J. Med. (2001) 344:1959–1965.
   Google Scholar
• TUOMISTO TT, KORKEELA A, RUTANEN J et al: Gene expression in macrophage-rich inflammatory cell infiltrates in human atherosclerotic lesions as studied by laser microdissection and DNA array: overexpression of HMG-CoA reductase, colony stimulating factor receptors, CD11A/CD18 integrins, and interleukin receptors. Arterioscler. Thromb. Vase. Biol. (2003) 23:2235–2240.
   PubMedGoogle Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• BRASIER AR, RECINOS A 3rd, ELEDRISI MS: Vascular inflammation and the renin-angiotensin system. Arterioscler. Thromb. Vase. Biol. (2002) 22:1257–1266.
   PubMed Web of Science ®Google Scholar
• GULLESTAD L, AUKRUST P, UELAND T et al.: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll Cardiol (1999) 34:2061–2067.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-PRESA M, BUSTOS C, ORTEGA M et al: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation (1997) 95:1532–1541.
   PubMed Web of Science ®Google Scholar
• •An interesting study showing anti-inflammatory effects of ACE inhibitors.
   Google Scholar
• LAZAR MA: Progress in cardiovascular biology: PPAR for the course. Nat. Med. (2001) 7:23–24.
   PubMed Web of Science ®Google Scholar
• MARX N, KEHRLE B, KOHLHAMMER K et al.: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. (2002) 90:703–710.
   PubMed Web of Science ®Google Scholar
• LI AC, BROWN KK, SILVESTRE MJ, WILLSON TM, PALINSKI W, GLASS CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clia Invest. (2000) 106:523–531.
   PubMed Web of Science ®Google Scholar
• ••An interesting paper describing the effectsof PPAR-y ligands in atherogenesis.
   Google Scholar
• DESPRES JP, LEMIEUX I, PASCOT A et al.: Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler. Thromb. Vase. Biol. (2003) 23:702–703.
   PubMed Web of Science ®Google Scholar
• NANNIZZI-ALAIMO L, ALVES VL, PHILLIPS DR: Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation (2003) 107:1123–1128.
   PubMed Web of Science ®Google Scholar
• PRASAD KS, ANDRE P, YAN Y, PHILLIPS DR: The platelet CD4OL/GP IIb-IIIa axis in atherothrombotic disease. Curl: Opin. Hematol (2003) 10:356–361.
   Google Scholar
• HERMANN A, RAUCH BH, BRAUN M, SCHROR K, WEBER AA: Platelet CD40 ligand (CD4OL)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets (2001) 12:74–82.
   PubMed Web of Science ®Google Scholar
• HERBERT JM: Effects of ADP-receptorantagonism beyond traditional inhibition of platelet aggregation. Expert. Opin. Investig. Drugs. (2004) 13:457–460.
   PubMed Web of Science ®Google Scholar
• WU KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin. Vase. Med. (2003) 3:107–112.
   PubMedGoogle Scholar
• YUSUF S, DAGENAIS G, POGUE J, BOSCH J, SLEIGHT P: Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:154–160.
   PubMed Web of Science ®Google Scholar
• CHARD IF, TAUBMAN MB: Chemokines in the pathogenesis of vascular disease. Circ. Res. (2004) 95:858–866.
   PubMedGoogle Scholar
• •A thorough review on the pathogenic role of chemokines in atherosclerosis.
   Google Scholar
• BARNES DA, TSE J, KAUFHOLD et al:Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. Clin. Invest. (1998) 101:2910–2919.
   Google Scholar
• GRONE HJ, WEBER C, WEBER KS et al.: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. (1999) 13:1371–1383.
   PubMed Web of Science ®Google Scholar
• GONG JH, RATKAY LG, WATERFIELD JD, CLARK-LEWIS I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in MRL-lpr mouse model. I Exp. Med. (1997) 186:131–137.
   PubMed Web of Science ®Google Scholar
• BAI X, CHEN JD, YANG AG, TORTI F, CHEN SY: Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Therapy (1998) 5:984–994.
   PubMed Web of Science ®Google Scholar
• NI W, EGASHIRA K, KITAMOTO S et al: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation (2001) 103:2096–2101.
   PubMed Web of Science ®Google Scholar
• ••An interesting study describing the anti-atherogenic effects of transfecting an N-terminal deletion mutant of the human mcp-1 gene into a remote organ.
   Google Scholar
• DAMAS JK, WiEHRE T, YNDESTAD A et al: Stromal cell-derived factor- lalpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation (2002) 106:36–42.
   PubMedGoogle Scholar
• SCHONBECK U, LIBBY P: CD40 signaling and plaque instability. Circ. Res. (2001) 89:1092–1103.
   PubMed Web of Science ®Google Scholar
• AUKRUST P, MULLER, UELAND T et al: Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation (1999) 100:614–620.
   Google Scholar
• SCHONBECK U, LIBBY P: The CD40/ CD154 receptor/ligand dyad. Cell. Mol Life Sci. (2001) 58:4–43.
   PubMed Web of Science ®Google Scholar
• LUTGENS E, GORELIK L, DAEMEN MJ et al.: Requirement for CD154 in the progression of atherosclerosis. Nat. Med. (2002) 8:247–252.
   PubMedGoogle Scholar
• ••An early study on the important role ofCD4OL in late atherosclerotic changes and plaque destabilisation.
   Google Scholar
• LUTGENS E, CLEUTJENS KB, HEENEMAN S, KOTELIANSKY VE, BURKLY LC, DAEMEN MJ: Both early and delayed anti-CD4OL antibody treatment induces a stable plaque phenotype. Proc. Natl. Acad. Sci. USA (2000) 97:7464–7469.
   PubMed Web of Science ®Google Scholar
• ANDRE P, PRASAD KS, DENIS CV et al: CD4OL stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat. Med. (2002) 8:247–252.
   PubMed Web of Science ®Google Scholar
• ••An important study showing that CD4OLseems to be an a2,03 ligand and necessary for stability of arterial thrombi.
   Google Scholar
• KAWAI T, ANDREWS D, COLVIN RB, SACHS DH, COSIMI AB: Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. (2000) 6:114.
   Web of Science ®Google Scholar
• MALLAT Z, BESNARD S, DURIEZ M et al.: Protective role of interleukin-10 in atherosclerosis. Circ. Res. (1999) 85:e17–e24.
   PubMed Web of Science ®Google Scholar
• ••A detailed study in IL-th-deficient miceshowing that IL-10 appears to be a crucial protective factor against development of atherosclerosis.
   Google Scholar
• WiEHRE T, HALVORSEN B, DAM/86 JK et al.: Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur. Clia Invest. (2002) 32:803–810.
   Google Scholar
• UYEMURA K, DEMER LL, CASTLE SC et al.: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. (1996) 97:2130–2138.
   PubMed Web of Science ®Google Scholar
• HALVORSEN B, WiEHRE T, SCHOLZ H et al: Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. I Lipid. Res. (2005) 46:211–219.
   PubMed Web of Science ®Google Scholar
• SMITH DA, IRVING SD, SHELDON J, COLE D, KASKI JC: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation (2001) 104:746–749.
   PubMed Web of Science ®Google Scholar
• TERKELTAUB RA: IL-10: An 'immunologic scalpel' for atherosclerosis? Arterioscler. Thromb. Vasc. Biol. (1999) 19:2823–2825.
   PubMed Web of Science ®Google Scholar
• CALAMIA KT: Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adv. Exp. Med. Biol. (2003) 528:545–549.
   PubMed Web of Science ®Google Scholar
• CALABRESE LH: Molecular differences in anticytokine therapies. Clia Exp. Rheumatel (2003) 21:241–248.
   PubMed Web of Science ®Google Scholar
• KIRII H, NIWA T, YAMADA Yet al.: Lack of interleukin-lbeta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2003) 23:656–660.
   PubMed Web of Science ®Google Scholar
• SUZUKI K, MURTUZA B, SMOLENSKI RT et al: Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation (2001) 104:1308–1313.
   Google Scholar
• DINARELLO CA: Therapeutic strategiesto reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol (2004) 4:378–385.
   PubMed Web of Science ®Google Scholar
• COMINELLI F: Cytokine-based therapies for Crohn's disease-new paradigms. N Engl. J. Med. (2004) 351:2045–2048.
   PubMed Web of Science ®Google Scholar